Citation

McFate Smith W, Davies RO, Gabriel MA, Kramsch DM, Moncloa F, Rush JE, Walker JF. Br. J. Clin. Pharmacol. 1984; 18(Suppl 2): 249S-253S, 255S.

Copyright

(Copyright © 1984, John Wiley and Sons)

DOI

unavailable

PMID

6099740

PMCID

PMC1463465

Abstract

Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. Over 3500 patients world-wide have received enalapril or enalaprilat. Long-term experience at present includes over 2500 patients. While enalapril and captopril produce similar efficacy, enalapril is better tolerated and appears not to be associated with occurrence of captopril-type side-effects, particularly the skin rash, taste loss, leukopenia and proteinuria. Enalapril and other converting enzyme inhibitors may be associated with renal insufficiency when given to patients with bilateral renovascular hypertension.

Language: en